Description: Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. The company was founded in 2017 and is headquartered in Blacksburg, Virginia.
Home Page: landosbiopharma.com
LABP Technical Analysis
1800 Kraft Drive
Blacksburg,
VA
24060
United States
Phone:
540 218 2232
Officers
| Name | Title |
|---|---|
| Mr. Timothy M. Mayleben M.B.A. | Principal Financial Officer & Director |
| Dr. Josep Bassaganya-Riera DVM, Ph.D. | Advisor |
| Mr. Gregory Oakes | Pres, CEO & Director |
| Mr. Patrick Truesdell | Principal Accounting Officer |
| Dr. Fabio Cataldi M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2437 |
| Price-to-Sales TTM: | 2.3706 |
| IPO Date: | 2021-02-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 46 |